Pharma News, 2022

The FDA has approved Cellular Biomedicine’s Investigational New Drug (IND) application for its tumor infiltrating lymphocyte (TIL) drug candidate C-TIL051 for late-stage non-small cell lung cance...

Viral DNA in human genomes, embedded there from ancient infections, serve as antivirals that protect human cells against certain present-day viruses, according to new research. ...

The C-reactive protein (CRP) score may be the most effective inflammation-based score to predict the overall survival (OS) of patients with intrahepatic cholangiocarcinoma (ICC) treated with anti-p...

Neural implants can help treat brain disorders such as Parkinson's disease and epilepsy by directly modulating abnormal activities — and the University of Toronto's Xilin Liu is working with mic...

Patients with CD5-positive relapsed/refractory peripheral T-cell lymphoma may derive benefit from MT-101, which was granted fast track designation by the FDA.

ITM Isotope Technologies Munich has received FDA’s Fast Track designation for ITM-11, an investigational radiopharmaceutical for the treatment of gastroenteropancreatic neuroendocrine tumors. ...

Patients with acute myeloid leukemia, the most common type of adult blood cancer, show large-scale genomic mutations and altered DNA folding patterns that could help identify potential therapeutic ...

An injection can help the overweight lose nearly a tenth of their body weight in just a few months, claim scientists. Researchers say the drug – yet to be named – hijacks a patient's appetite-r...

In a small real-world cohort, annualized relapse rates were reduced for patients with multiple sclerosis who switched to cladribine (Mavenclad; EMD Serono) from ocrelizumab (Ocrevus; Genentech), na...

Stevanato Group S.p.A., a global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, and DWK Life Sciences, a global manufacturer...

GSK has said it will not be able to move ahead with regulatory filings for otilimab as a treatment for rheumatoid arthritis (RA), after it failed to show the desired level of efficacy in two phase ...

The FDA has granted an Orphan Drug designation to NovAccess Global’s for an investigational immunotherapy for aggressive brain cancers such as glioblastoma.